title: 15th International Conference on Human Antibodies and Hybridomas. 14-16 April 2010, Tiara Park Atlantico Hotel, Porto, Portugal.
abstract: Antibodies and antibody conjugates are currently one of the largest classes of new drug entities under development. These versatile molecules are being investigated for the treatment of many pathological conditions, such as cancer and infectious, inflammatory and autoimmune diseases. Antibodies can exert biological effects as naked antibodies by themselves, or can be used as delivery agents conjugated with various drugs (e.g., immunoconjugates) and as tools of multistep targeting. Site-specific delivery of therapeutic agents has been the ultimate goal of the pharmaceutical industry, as it has the potential to maximize drug efficiency while minimizing side effects. Antibodies have much potential for this objective. Thus, it is useful to summarize some of the main strategies currently being employed for the development of these diverse therapeutic molecules and to highlight the recent novelties in the field. These goals were the focus of the 15th International Conference on Human Antibodies and Hybridomas, held during 14-16 April 2010 in Porto, Portugal.
authors.affiliation: Center of Surgical & Molecular Tumorpathology, National Institute of Oncology, Budapest, Hungary. kotlanb@netscape.net
authors.forename: Beatrix
authors.initials: B
authors.lastname: Kotlan
mesh_terms: D000818:Animals; D030801:Animals, Genetically Modified; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003141:Communicable Diseases / Q000276:immunology / Q000628:therapy*; D006801:Humans; D006825:Hybridomas; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D051381:Rats
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents